2025
Sorafenib Alters Interstitial Proton and Sodium Levels in the Tumor Microenvironment: A 1H/23Na Spectroscopic Imaging Study
Khan M, Walsh J, Kurdi S, Mishra S, Mihailović J, Coman D, Hyder F. Sorafenib Alters Interstitial Proton and Sodium Levels in the Tumor Microenvironment: A 1H/23Na Spectroscopic Imaging Study. NMR In Biomedicine 2025, 38: e5319. PMID: 39764672, DOI: 10.1002/nbm.5319.Peer-Reviewed Original ResearchConceptsU87 tumorsSorafenib-treated tumorsUpregulated aerobic glycolysisSodium-potassium pumpInterstitial spaceTumor microenvironmentIntracellular NaTumor growthSpectroscopic imaging studiesTumor invasionGlioblastoma modelSodium levelsTumorGlioblastoma therapyImaging studiesPlaceboSorafenibMetabolic changesImmune functionCancer hallmarksAerobic glycolysisProliferative stateMeasure treatment effectsIonic changesProliferation rate
2024
CEACAM5-Targeted Immuno-PET in Androgen Receptor–Negative Prostate Cancer
Imberti C, De Gregorio R, Korsen J, Hoang T, Khitrov S, Kalidindi T, Nandakumar S, Park J, Zaidi S, Pillarsetty N, Lewis J. CEACAM5-Targeted Immuno-PET in Androgen Receptor–Negative Prostate Cancer. Journal Of Nuclear Medicine 2024, 65: 1043-1050. PMID: 38782457, PMCID: PMC11218725, DOI: 10.2967/jnumed.123.267107.Peer-Reviewed Original ResearchConceptsNeuroendocrine prostate cancerCarcinoembryonic antigen-related cell adhesion molecule 5CEACAM5 expressionProstate cancerAggressive neuroendocrine prostate cancerAndrogen receptor (AR)-negativeEx vivo organ distributionXenograft prostate cancer modelsProstate cancer cell linesProstate cancer modelCell line LNCaP.Immuno-PET imagingCell line PC3Prostate cancer hallmarksCancer cell linesCancer modelsRadiolabeled antibodiesImmuno-PETSurface antigensProstatePET imagingCancerCancer hallmarksWestern blottingCell lines
2023
Cancer Evolution: A Multifaceted Affair
Ciriello G, Magnani L, Aitken S, Akkari L, Behjati S, Hanahan D, Landau D, Lopez-Bigas N, Lupiáñez D, Marine J, Martin-Villalba A, Natoli G, Obenauf A, Oricchio E, Scaffidi P, Sottoriva A, Swarbrick A, Tonon G, Vanharanta S, Zuber J. Cancer Evolution: A Multifaceted Affair. Cancer Discovery 2023, 14: of1-of13. PMID: 38047596, PMCID: PMC10784746, DOI: 10.1158/2159-8290.cd-23-0530.Peer-Reviewed Original ResearchConceptsEvolutionary mechanismsMultiple evolutionary mechanismsCancer evolutionHeritable genetic changesTumor evolutionImprove personalized medicineEpigenetic reprogrammingGenetic changesTumor microenvironmentGenetic instabilityCancer hallmarksEvolutionary toolkitNongenetic mechanismsCancer cellsPersonalized medicineBiomarker discoveryTumor cellsTumor progressionTumorComprehensive characterizationMolecular modificationsCancerCellsChromatinReprogramming
2021
The Coevolution of Placentation and Cancer
Wagner GP, Kshitiz, Dighe A, Levchenko A. The Coevolution of Placentation and Cancer. Annual Review Of Animal Biosciences 2021, 10: 1-21. PMID: 34780249, DOI: 10.1146/annurev-animal-020420-031544.Peer-Reviewed Original ResearchStructural Insights into Pseudokinase Domains of Receptor Tyrosine Kinases
Sheetz J, Mathea S, Karvonen H, Malhotra K, Chatterjee D, Niininen W, Perttila R, Preuss F, Suresh K, Stayrook S, Tsutsui Y, Radhakrishnan R, Ungureanu D, Knapp S, Lemmon M. Structural Insights into Pseudokinase Domains of Receptor Tyrosine Kinases. The FASEB Journal 2021, 35 DOI: 10.1096/fasebj.2021.35.s1.02446.Peer-Reviewed Original ResearchReceptor tyrosine kinasesPseudokinase domainTyrosine kinaseTyrosine kinase-mediated signalingKey cellular processesKinase-mediated signalingExtracellular cuesViable drug targetTransduce signalsCellular processesEmbryonic developmentPseudokinasesTissue homeostasisFuture dissectionReceptor dimerizationStructural insightsKinase activityCancer hallmarksSignaling mechanismDrug targetsPutative routesKinaseOncogenic driversSmall moleculesPhosphotransferImaging extracellular acidification and immune activation in cancer
Hyder F, Coman D. Imaging extracellular acidification and immune activation in cancer. Current Opinion In Biomedical Engineering 2021, 18: 100278. PMID: 33997581, PMCID: PMC8115219, DOI: 10.1016/j.cobme.2021.100278.Peer-Reviewed Original ResearchGene-centric viewMetabolic reprogrammingHostile ecosystemCancer hallmarksHabitat acidificationHost cellsFuture cancer therapyAerobic glycolysisDiverse mechanismsMetabolic interactionsExtracellular acidificationDifferent nutrientsCancer cellsImmune cellsDisease tissuesCellsTumor milieuNutrientsCancer therapyMetabolismRecent evidenceIncidental phenomenonAcidificationReprogrammingOncogene
2014
Effects of Obesity on Transcriptomic Changes and Cancer Hallmarks in Estrogen Receptor–Positive Breast Cancer
Fuentes-Mattei E, Velazquez-Torres G, Phan L, Zhang F, Chou PC, Shin JH, Choi HH, Chen JS, Zhao R, Chen J, Gully C, Carlock C, Qi Y, Zhang Y, Wu Y, Esteva FJ, Luo Y, McKeehan WL, Ensor J, Hortobagyi GN, Pusztai L, Symmans W, Lee MH, Yeung SC. Effects of Obesity on Transcriptomic Changes and Cancer Hallmarks in Estrogen Receptor–Positive Breast Cancer. Journal Of The National Cancer Institute 2014, 106: dju158. PMID: 24957076, PMCID: PMC4110474, DOI: 10.1093/jnci/dju158.Peer-Reviewed Original ResearchMeSH KeywordsAdipocytesAdipokinesAgedAnimalsAntineoplastic AgentsBiomarkers, TumorBreast NeoplasmsCell ProliferationDisease Models, AnimalEverolimusFemaleHumansKaplan-Meier EstimateMetforminMiceMice, TransgenicMiddle AgedObesityPostmenopauseProspective StudiesProto-Oncogene Proteins c-aktReceptors, EstrogenSignal TransductionSirolimusTOR Serine-Threonine KinasesTranscriptomeConceptsEstrogen receptor-positive breast cancerReceptor-positive breast cancerBreast cancer cell proliferationEffect of obesityBreast cancer patientsObese mouse modelAdipocyte-secreted adipokineCancer cell proliferationCancer patientsBreast cancerMouse modelCell proliferationAssociation of obesityAkt/mTOR activationMammary tumor growthEpithelial-mesenchymal transition genesAKT/mTOR pathwayBreast cancer aggressivenessBreast tumor formationCancer hallmarksPostmenopausal womenPretreatment biopsiesProspective cohortAdipokine secretionCancer death
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply